As expected, the treatment of RKO cells with a dual SphK1/SphK2 inhibitor significantly increased cytotoxic effects of oxaliplatin, which suggests that SphK1 and SphK2 regulate chemosensitivity of BRAF mutant colon cancer cells. Here, SPHK2 is linked to malignant colon neoplasm.